PROLIFERATION OF CIRCULATING HEMATOPOIETIC STEM CELLS IN CHRONIC RENAL FAILURE
Keywords:
chronic renal failure, uremia, circulating stem cells, BFU E, CFU GM, CFU GEMM, anemiaAbstract
Background. The cause of anemia in chronic renal failure seems to be multifactorial. The aim of our investigation was to verify the hypothesis that the causes of anemia are at a higher stem cell level. Therefore, beside peripheral blood BFU E which require erythropoietin, we cultivated peripheral blood stem cells which do not require it – CFU GM and CFU GEMM.
Patients and methods. Peripheral blood BFU E, CFU GM and CFU GEMM were studied in 65 uremic patients who were placed on maintenance hemodialysis three times weekly. All were anemic. In regard to creatinine concentration they were divided into Group 1 with creatinine concentration < 900 µmol/L (24 pts) and Group 2 with creatinine concentration > 900 µmol/L (41 pts).
Hematopoietic colony-forming cells from blood were assayed in a methylcellulose culture with growth factor addition.
Results. The growth of colonies BFU E and CFU GM was significant inhibited in whole group of patients, growth of CFU GEMM was significantly inhibited in the Group 2. A positive correlation of the CFU GM and BFU E, CFU GEMM and BFU E and CFU GM and CFU GEMM colonies was found in the whole group of patients. There was a negative correlation between the growth of the CFU GEMM, CFU GM and BFU E colonies and the urea concentration in the entire group of patients. In Group 1 a negative correlation was found between the growth of the BFU E and CFU GM colonies and creatinine concentration. In the Group 2 a negative correlation between growth of the BFU E and CFU GM and urea concentration was found.
Conclusions. According to our study, erythropoetin concentration, although normal, is still too low with regard to the grade of anemia. In patients the number of stem cell colonies was decreased significantly, correlating with the severity of uremia. This confirms the hypothesis that disturbed hematopoiesis in uremia is affected by additional factors and that their influence in uremia is permanent.
Downloads
References
Abboud CN, Liesveld JL. Granulopoiesis and monocitopoiesis. In : Hoffman R, Benz EJ, Jr, Shattil SJ et al. Basic principles and practice, 2 nd ed. New York, Edinburgh, London: Churchil Livingstone 1995: 255–86.
Molecular biology and cytokines. In: Munker R, Hiller E, Paquette R eds. Modern hematology. Totowa, New Jersey: Humana Press 2000: 19–34.
Eschbach JW, Adamson JW, Cook JD. Disorders of red blood cell production in uremia. Arch Intern Med 1970; 126: 812–5.
Radtke HW, Rege AB, La Marche MB, Bartos D et al. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 1981; 61: 1623–9.
Meytes D, Bogin EMA, Dukex PP, Masry G. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981; 67: 1263–9.
Eschbach JW. Hemathological problems of dialysis patients. In: Maher JF ed. Replacement of renal function by dialysis. 3rd ed. Dordrecht, Boston, Lancaster: Kluwer Academic Publishers 1989: 851–64.
Morra L, Ponassi G, Gurreri F, Moccia F, Caristo G et al. Alterations of erythropoiesis in chronic uremic patients treated with intermittent hemodialysis. Biomedicine & Pharmacotherapy 1987; 41: 396–9.
Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia in chronic disease. Blood 1992; 80: 1639–47.
Williams DA. Stem cell model of hematopoiesis. In : Hoffman R, Benz EJ, Jr, Shattil SJ et al. Basic principles and practice. 2nd ed. New York, Edinburgh, London: Churchil Livingstone 1995: 180–92.
Matsuzaki Y, Mizuguchi T, Kosaka M, Saito S. Analysis of circulating hematopoietic progenitors in patients with chronic renal failure under hemodialysis. Int J Hematol 1995; 63: 33–40.
De Klerk G, Wilmink JM, Rosengarten PCJ, Vet RJWM et al. Serum erythropoietin titers in anemia of chronic renal failure. J Lab Clin med 1982; 100: 720– 34.
Pavletic Z, Labar B. Hematopoetski faktori rasta. Lijec Vjes 1990; 112: 339–46.
Corazza F, Bergmann P, Dratwa M, Guns M, Fondu P. Responsiveness to recombinant erythropoietin therapy in end stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors. Nephrol Dial Tranplant 1992; 7: 311–7.
Allen DA, Breen C, Yaqoob MM, Mac Dougall IC. Inhibition of CFU E colony formation in uremic patients with inflammatory disease: role of IFN ă and TNF á. J Invent Med 1999; 47: 204–11.
Labar B. Eritrocitopoeza, biokemija i funkcija eritrocita. In: Jakšić B, Labar B, Grgičević D eds. Hematologija i transfuziologija. Zagreb: UMENA, 1989: 23–32.
Morra L, Ponassi AG, Gurreri G, Moccia F, Mela GS et al. Inadequate ability of T lymphocytes from chronic uremic subjects to stimulate the in vitro growth of commited erythroid progenitors (BFU E). Acta Haematol 1988; 79: 187– 91.
Girndt M, Sester M, Sester U, Kaul H, Köhler H. Molecular aspects of T and B cell function in uremia. Kidney Int 2001; 59: 206–11.
Bier V, Debantin KM, Bosh A, Hoffman HG, Müller-Wiefe DE et al. Is interleukin (IL 3) a critical haematopoietic growth factor in uremia? Proc Eur Congr Dial Transplant 1990.
Downloads
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
